NANOVIRICIDES INC (NNVC)

US6300873022 - Common Stock

1.75  -0.01 (-0.57%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NNVC. NNVC was compared to 576 industry peers in the Biotechnology industry. While NNVC seems to be doing ok healthwise, there are quite some concerns on its profitability. NNVC is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NNVC has reported negative net income.
In the past year NNVC has reported a negative cash flow from operations.
NNVC had negative earnings in each of the past 5 years.
NNVC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NNVC's Return On Assets of -82.94% is on the low side compared to the rest of the industry. NNVC is outperformed by 72.43% of its industry peers.
NNVC has a Return On Equity (-89.28%) which is in line with its industry peers.
Industry RankSector Rank
ROA -82.94%
ROE -89.28%
ROIC N/A
ROA(3y)-38.17%
ROA(5y)-46.67%
ROE(3y)-40.8%
ROE(5y)-52.73%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NNVC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, NNVC has more shares outstanding
Compared to 5 years ago, NNVC has more shares outstanding
NNVC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

NNVC has an Altman-Z score of -3.94. This is a bad value and indicates that NNVC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.94, NNVC is doing worse than 60.03% of the companies in the same industry.
NNVC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.94
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

NNVC has a Current Ratio of 4.32. This indicates that NNVC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NNVC (4.32) is comparable to the rest of the industry.
NNVC has a Quick Ratio of 4.32. This indicates that NNVC is financially healthy and has no problem in meeting its short term obligations.
NNVC has a Quick ratio (4.32) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.32
Quick Ratio 4.32

More info and screens

1

3. Growth

3.1 Past

The earnings per share for NNVC have decreased strongly by -38.56% in the last year.
EPS 1Y (TTM)-38.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.12% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-12.5%
EPS Next 2Y-22.47%
EPS Next 3Y1.64%
EPS Next 5Y8.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NNVC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NNVC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.47%
EPS Next 3Y1.64%

More info and screens

0

5. Dividend

5.1 Amount

NNVC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOVIRICIDES INC

NYSEARCA:NNVC (7/5/2024, 5:40:00 PM)

1.75

-0.01 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap20.67M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.94%
ROE -89.28%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.32
Quick Ratio 4.32
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-38.56%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-12.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y